MCM PRV Reauthorization Act

Bill: 118-hr-5708
Sponsor: full_name: Rep. Finstad, Brad [R-MN-1]
Introduced: 2023-09-26
Policy area: Health
Subjects: Chemical and biological weapons

Health technology, devices, supplies

Infectious and parasitic diseases

Licensing and registrations

Prescription drugs

User charges and fees
Latest action: action_date: 2023-09-29
text: Referred to the Subcommittee on Health.

Summaries:

tv_txt: I 118th CONGRESS 1st Session H. R. 5708 IN THE HOUSE OF REPRESENTATIVES September 26, 2023 Mr. Finstad (for himself and Mr. Phillips ) introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act to extend a priority review program to encourage treatments for agents that present national security threats.

1. Short title This Act may be cited as the MCM PRV Reauthorization Act . 2. Extension of priority review to encourage treatments for agents that present national security threats Section 565A(g) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–4a(g)) is amended by striking 2023 and inserting 2033 .